PPARA and coronary artery disorder: Clinical experiments have found significantly reduced levels of plasma interleukin-6 (IL-6), interferon-α (IFN-α), and C-reactive protein (CRP) after taking the PPARα agonist (fibrate) in patients with coronary heart disease confirmed by angiography [14].